Media Releases
Date  Subject 
09/02/2010 Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy
26/01/2010 Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio
20/01/2010 Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression as published in New England Journal of Medicine
20/01/2010 Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer
18/01/2010 Novartis providing equivalent of over USD 2.5 million in immediate emergency aid for victims of Haiti earthquake
11/01/2010 Novartis launches schizophrenia treatment Fanapt in the US, offering patients an attractive alternative to existing medications
04/01/2010 Novartis to acquire majority control of Alcon, a global leader in eye care, and proposes merger for full ownership
23/12/2009 Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project relaxin for treatment of acute decompensated heart failure
21/12/2009 All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization (WHO) for use in developing world
18/12/2009 Novartis meningococcal vaccine Menveo® recommended for approval in the European Union for prevention of disease in adolescents and adults
09/12/2009 Novartis set to sustain its leading global position in oncology with portfolio targeting various tumors and life-threatening diseases
08/12/2009 Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
03/12/2009 Novartis receives approval in the European Union for Onbrez® Breezhaler®, a new once-daily bronchodilator for patients with COPD
27/11/2009 ''Tackling the crisis with a new world economic ethics'': experts debate at the Novartis Foundation Symposium in Basel, Switzerland
25/11/2009 Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
24/11/2009 Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
17/11/2009 Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)
13/11/2009 Novartis receives approval in Switzerland for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine
12/11/2009 Novartis launches Prevacid®24HR over-the-counter for full 24-hour frequent heartburn treatment
05/11/2009 Novartis receives regulatory approval in Germany for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine
04/11/2009 Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan
03/11/2009 Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
29/10/2009 Novartis on track to deliver Influenza A (H1N1) vaccine for the US
28/10/2009 Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease
23/10/2009 Novartis receives approval in the European Union for Exforge HCT®, a new 3-in-1 treatment for high blood pressure
22/10/2009 Novartis delivers strong new product momentum and operational performance in first nine months of 2009
20/10/2009 New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid
20/10/2009 Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® as first-line treatment in chronic myeloid leukemia patients
19/10/2009 Novartis receives Complete Response letter from FDA for QAB149, an investigational bronchodilator for COPD
19/10/2009 Leading Dengue and TB scientists discuss new clinical research approaches and models of excellence for clinical research and trials in endemic regions
12/10/2009 Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM), an FDA-approved oral therapy for schizophrenia
08/10/2009 Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
06/10/2009 Novartis completes shipment of US supply of Fluvirin® seasonal influenza vaccine
05/10/2009 Sandoz launches somatropin, the first-ever Japanese biosimilar, increasing access to key medicines in second largest global market
30/09/2009 Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
25/09/2009 Novartis bronchodilator QAB149 recommended for approval in European Union to treat patients with chronic obstructive pulmonary disease
25/09/2009 Novartis A(H1N1) Pandemic Influenza vaccine Focetria® receives positive opinion from CHMP
24/09/2009 Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines
17/09/2009 Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
15/09/2009 Novartis investigational bronchodilator QAB149 improves lung function and reduces breathlessness compared to tiotropium in patients with COPD
03/09/2009 Novartis MF59® adjuvanted cell culture-based vaccine shows strong immune response in A(H1N1) clinical trials
01/09/2009 Novartis hosts scientific symposium in Philippines to review research approaches, clinical management, and growing presence of Dengue
24/08/2009 Novartis receives approval in EU for Xolair® to treat children age 6 to 11 years suffering from severe persistent allergic asthma
24/08/2009 Novartis unveils Lab of Future concept to top European students at Biotechnology Leadership Camp (BioCamp)
19/08/2009 Results in The New England Journal of Medicine confirm Novartis drug Femara® is superior to tamoxifen after breast cancer surgery
17/08/2009 US FDA approves Extavia® - the first in a new portfolio of planned MS therapies from Novartis to help patients with this devastating disease
11/08/2009 Sandoz launches first generic version of Prograf® capsules
06/08/2009 Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer after failure of targeted therapy
05/08/2009 Novartis begins shipment of Fluvirin® seasonal influenza vaccine for the U.S. market ahead of schedule
24/07/2009 Ilaris® recommended for European approval as new biologic drug to treat a rare but serious group of auto-inflammatory diseases
21/07/2009 FDA approves Tekturna HCT® as initial treatment in patients unlikely to achieve their blood pressure goal with a single agent
16/07/2009 Novartis delivers strong operational performance in the first half of 2009 driven by sustained Pharmaceuticals innovation
08/07/2009 Japanese Ministry of Health approves Rasilez®, a first-in-class direct renin inhibitor (DRI), for the treatment of high blood pressure
07/07/2009 Novartis extends tuberculosis drug donation to Tanzania
06/07/2009 Novartis delivers 250,000,000th Coartem® treatment and becomes first healthcare company to join United Against Malaria partnership
01/07/2009 Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo®
26/06/2009 Once-yearly Aclasta® approved in EU to treat osteoporosis caused by steroid treatment in men and postmenopausal women
25/06/2009 Sandoz receives approval for first-ever Japanese biosimilar
24/06/2009 Afinitor® and Sandostatin® LAR® Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months
18/06/2009 New biological therapy Ilaris® approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease
12/06/2009 Novartis successfully demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine
08/06/2009 Afinitor® Phase II data show positive results for patients with multiple types of lymphoma, leading to Phase III trial
05/06/2009 Tasigna® shows rapid and deep responses in newly diagnosed patients with a form of chronic myeloid leukemia
04/06/2009 Novartis announces typhoid vaccine research program in partnership with the Wellcome Trust
03/06/2009 One-year Phase III study confirms Ilaris® offers long-term remission in patients with CAPS, a severe lifelong auto-inflammatory disease
02/06/2009 Novartis successfully launches EUR 1.5 billion notes issue
01/06/2009 FDA approves Reclast® to prevent osteoporosis in postmenopausal women with convenient less frequent dosing
29/05/2009 Afinitor® recommended for use in the European Union for patients with advanced kidney cancer
28/05/2009 Data on more than 15 Novartis Oncology compounds at ASCO highlight progress toward targeted therapies for diverse tumor types
28/05/2009 Novartis increases its offer price on Novartis India Ltd.
26/05/2009 Novartis to enter Japan vaccines market through agreement for Haemophilus Influenzae Type B (Hib) vaccine
21/05/2009 Phase III data show Novartis investigational bronchodilator QAB149 significantly improves lung function over current treatments in COPD[1],[2]
20/05/2009 Sandoz to acquire EBEWE Pharma specialty generics business, improving access for patients worldwide to injectable cancer drugs
19/05/2009 Novartis announces restructuring of global collaboration with Schering-Plough to develop fixed-dose combination respiratory therapies
14/05/2009 Novartis receives approval from FDA to market Prevacid®24HR as first and only OTC proton pump inhibitor in original formulation
13/05/2009 Scientists who developed Novartis Coartem® and Glivec® receive 2009 ''European Inventor of the Year'' awards
13/05/2009 Novartis names Jonathan Symonds deputy CFO and CFO designate
07/05/2009 Glivec® approved in EU as first post-surgery therapy to reduce risk of cancer returning in patients with aggressive gastrointestinal tumors
30/04/2009 FDA approves Exforge HCT® - the only high blood pressure treatment to combine three medications in a single pill
30/04/2009 Novartis investigational adjuvanted (MF59) pre-pandemic avian influenza vaccine Aflunov® shows long lasting, broadly cross-protective immune response
29/04/2009 New data presented at American Academy of Neurology congress show 80-83% of MS patients on oral FTY720 were relapse-free for one year - significantly better than a leading current treatment
23/04/2009 Pharmaceuticals delivers strong underlying growth in first quarter of 2009 as Novartis continues to rejuvenate product portfolio
08/04/2009 Coartem® receives FDA approval becoming first artemisinin-based combination treatment (ACT) for malaria in the US
02/04/2009 Ixiaro® vaccine receives Marketing Authorization in Europe for the prevention of Japanese Encephalitis
30/03/2009 Ixiaro® receives FDA approval for the prevention of Japanese Encephalitis
30/03/2009 Afinitor® approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib
25/03/2009 Novartis makes an open offer to increase stake in Novartis India Ltd.
19/03/2009 Glivec® recommended for use in Europe as first post-surgery treatment for gastrointestinal stromal tumors (GIST)
18/03/2009 Glivec® substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors, The Lancet reports
24/02/2009 Novartis shareholders approve 25% dividend increase at 2009 Annual General Meeting
13/02/2009 Sandoz receives European Commission approval for biosimilar filgrastim
12/02/2009 Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound with potential to reduce risk of heart attack and stroke
11/02/2009 Zometa® reduces risk of breast cancer recurrence in premenopausal women, study in The New England Journal of Medicine reports
05/02/2009 Novartis successfully launches USD 5 billion bond issue
28/01/2009 Novartis increases dividend by 25% based on strong 2008 results from strategic healthcare portfolio
27/01/2009 Novartis and Gen-Probe Agree to Extend and Expand Blood Screening Collaboration
27/01/2009 Novartis and Medicines for Malaria Venture launch Coartem® Dispersible, the first ACT* developed for children suffering from malaria
22/01/2009 Novartis launches Extavia®, a new therapeutic option to help patients combat devastating symptoms of multiple sclerosis
21/01/2009 Four innovative Novartis medicines for cancer, asthma, high blood pressure and wet AMD approved in Japan
15/01/2009 US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine
14/01/2009 New study first to confirm Sandostatin® LAR® controls tumor growth in patients with rare gastrointestinal tumors
14/01/2009 Afinitor® Phase II trial results positive in patients with advanced gastric cancer after failure of one or more prior treatments
29/12/2008 Novartis strengthens vaccine pipeline with agreement for novel CMV vaccines candidate
20/12/2008 Glivec receives US approval as first treatment to reduce risk of cancer returning in patients with gastrointestinal stromal tumors
13/12/2008 Afinitor® shows potential to reverse resistance to Herceptin®[*] in metastatic breast cancer patients, leading to Phase III trial
12/12/2008 First Phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a
11/12/2008 New data show Zometa® enhances impact of chemotherapy on reducing breast tumor size
11/12/2008 Femara® first aromatase inhibitor to indicate survival benefit versus tamoxifen when taken for five years after breast cancer surgery
11/12/2008 Novartis receives China Charity Award for relief efforts to Chinese earthquake victims
09/12/2008 Exjade® benefits chronically transfused patients by significantly reducing toxic iron that can damage key organs, according to landmark trial
08/12/2008 Tasigna® demonstrates rapid response as initial therapy in life-threatening form of leukemia
04/12/2008 Novartis awards program continues to drive energy savings and environmental progress
04/12/2008 ''Dare to dialog?'' - experts debate on the conditions of constructive stakeholder relations at this year's symposium of the Novartis Foundation for Sustainable Development
04/12/2008 More than 200 abstracts at ASH and SABCS reveal potential compelling patient benefits from Novartis Oncology current and pipeline therapies
21/11/2008 Sandoz receives positive EU opinion for biosimilar filgrastim
21/11/2008 Rasilez HCT® receives recommendation for European approval as a single-pill combination to treat high blood pressure
19/11/2008 Novartis highlights innovative approach to drug discovery with dynamic advance in exploratory pipeline
11/11/2008 Rasilez®, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older
29/10/2008 Rasilez HCT®, single-pill combination of Rasilez® and diuretic, receives Swiss approval for the treatment of high blood pressure
27/10/2008 ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases
21/10/2008 Novartis to acquire Nektar Therapeutics pulmonary business unit, strengthening respiratory drug delivery capabilities
20/10/2008 Novartis delivers sustained strong performance in first nine months of 2008 underpinned by accelerating growth in pharmaceuticals
08/10/2008 Early data show potential for imatinib to treat life-threatening form of pulmonary artery disease
07/10/2008 New Phase II data on NVA237, a novel once-daily treatment for COPD, show promising efficacy and tolerability with potentially faster onset than tiotropium
06/10/2008 New study shows potential benefits of innovative Xolair® anti-IgE therapy in treating children suffering from moderate-to-severe allergic asthma
30/09/2008 Once-yearly Aclasta® approved in EU to treat osteoporosis in men and to reduce risk of new fractures following hip fracture both in men and postmenopausal women
25/09/2008 Novartis starts ''squeeze out'' procedure for remaining Speedel shares
19/09/2008 Novartis MF59®-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu
16/09/2008 Latest RAD001 study results show further increase in time without tumor growth in patients with advanced kidney cancer
15/09/2008 Novartis receives FDA priority review for Coartem®, potentially the first artemisinin-based combination treatment (ACT) for malaria in the US
13/09/2008 RAD001 combined with Sandostatin® LAR® and as monotherapy controls growth of rare pancreatic neuroendocrine tumors
10/09/2008 New Phase II data show Novartis investigational Meningitis B vaccine may also protect infants six months and older
09/09/2008 Data show Galvus® better tolerated by patients with type 2 diabetes, with no weight gain, a favorable cardiovascular profile and equal efficacy compared to widely-used TZDs
09/09/2008 RAD001 granted priority review in the US based on potential to fill unmet medical need in patients with advanced kidney cancer
03/09/2008 Rasilez® , first-in-class direct renin inhibitor, lowers high blood pressure more effectively than diuretic in obese patients
03/09/2008 Sandoz receives FDA approval for Omnitrope® Pen 10 with liquid cartridge
29/08/2008 Novartis decides not to pursue further development of Aurograb(TM)
27/08/2008 Glivec receives FDA priority review as first therapy to reduce recurrence of gastrointestinal stromal tumors after surgery
27/08/2008 NICE final guidance recommends Lucentis® as cost-effective treatment for wet AMD, a leading cause of blindness
07/08/2008 Novartis begins shipment to US of Fluvirin® Influenza Virus Vaccine with three new strains for the 2008-2009 influenza season
04/08/2008 Single-pill combinations Diovan HCT® and Exforge® approved in US as first-line treatments for high blood pressure
28/07/2008 Exforge® helps nearly twice as many patients control their high blood pressure compared to amlodipine alone
25/07/2008 Once-yearly Aclasta® recommended in EU to treat male osteoporosis and reduce risk of new fractures in patients after hip fracture
17/07/2008 Novartis gains momentum with strong performance in first half of 2008 from portfolio focused on growth areas of healthcare
11/07/2008 Novartis enters strategic partnership with Lonza to accelerate growth of biologics pipeline
10/07/2008 Novartis buys additional 51.7% stake in Speedel and announces plans to acquire remaining shares in a mandatory public tender offer
08/07/2008 Novartis completes acquisition of 25% stake in Alcon from Nestlé, first step toward majority ownership of the world leader in eye care
02/07/2008 Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
24/06/2008 Novartis Institute for Tropical Diseases and Global Alliance for TB Drug Development announce five-year collaboration targeted to accelerate TB treatment R&D
17/06/2008 Rasilez®[*] ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever
13/06/2008 Higher initial dose of Glivec achieved better early responses than standard dose for patients with chronic myeloid leukemia
12/06/2008 Novartis recommends rejection of ''mini-tender'' offer by TRC Capital for American Depositary Shares
10/06/2008 Novartis successfully issues two Swiss franc benchmark bonds totaling CHF 1.5 billion
05/06/2008 Leading blood pressure medication Diovan® with diuretic reduces key sign of artery ageing which is linked to risk of heart attack and stroke
05/06/2008 FDA broadens US indication for once-yearly Reclast® as only osteoporosis treatment approved for prevention of fractures after a hip fracture
04/06/2008 New data show potential of Rasilez®* to protect kidneys from damage independent of its proven ability to lower blood pressure
04/06/2008 Novartis gains rights to promising hospital antibiotic in clinical development through full acquisition of Protez Pharmaceuticals
04/06/2008 Novartis presents full pipeline of novel vaccines addressing significant unmet needs
02/06/2008 Early data presented at ASCO show potential of RAD001 to enhance efficacy of, and overcome resistance to, breast cancer treatments
31/05/2008 Major independent trial demonstrates significant anticancer benefit of Zometa® in women with early-stage breast cancer
26/05/2008 Extavia® approved in European Union for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis
19/05/2008 RAD001 more than doubles time without tumor growth after failure of standard treatment in patients with advanced kidney cancer
15/05/2008 Strength and innovation of Novartis Oncology products and pipeline with potential to improve patient treatment demonstrated by more than 170 abstracts at ASCO annual meeting
15/05/2008 New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone
14/05/2008 In a Phase II study, Novartis Meningitis B vaccine has potential to produce a protective immune response in infants[1], the age group most at risk
14/05/2008 Significant blood pressure reductions seen in difficult-to-treat, black patients receiving Exforge®-based therapy[1]
06/05/2008 Novartis Menveo® vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial
28/04/2008 Breakthrough technique pioneered at Novartis research institute restores light sensitivity in damaged retinas
23/04/2008 Novartis announces 20% average reduction in price of malaria drug Coartem® to further accelerate access in malaria-endemic regions
21/04/2008 Novartis reports higher sales and earnings in first quarter of 2008 showing healthcare portfolio well on the way to new growth cycle
15/04/2008 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
15/04/2008 Patients with early Parkinson's disease show better symptom control[1] and improvements in daily activities[1] with Stalevo than levodopa/carbidopa
11/04/2008 Study shows once-yearly Aclasta® better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids
11/04/2008 ASA404, a novel cancer agent, begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death
08/04/2008 ACZ885, a new biological drug in development, shows potential in treating serious life-long autoinflammatory diseases
07/04/2008 Novartis to further strengthen its healthcare portfolio by acquiring 25% stake in Alcon from Nestlé with right to take over majority ownership of the world leader in eye care
31/03/2008 Rasilez®* , the first-in-class direct renin inhibitor, reduces left ventricular hypertrophy, a powerful predictor of heart disease
12/03/2008 Sandoz enhances patient access with launch of Omnitrope(TM) Pen 5 with liquid cartridge
10/03/2008 Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
28/02/2008 Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy
26/02/2008 Novartis shareholders approve all resolutions at 2008 Annual General Meeting, including 19% dividend increase
25/02/2008 Eucreas®, a single-tablet combination of Galvus® and metformin, set for launch in first EU countries as new treatment for type 2 diabetes
22/02/2008 New Novartis Research Institute first to focus on innovative vaccines for the developing world
01/02/2008 Novartis announces proposals for shareholder approval at next Annual General Meeting
01/02/2008 Galvus®, a new treatment for patients with type 2 diabetes, receives European approval for label update paving the way for EU launches
31/01/2008 Novartis files its Form 20-F annual report with the US Securities and Exchange Commission
21/01/2008 Tekturna HCT®, a single-tablet combination of Tekturna®* and a diuretic, receives US approval for treatment of high blood pressure
17/01/2008 Novartis achieves record results in 2007 underscoring benefits of strategic healthcare portfolio
08/01/2008 New data show Menveo(TM) to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants
17/12/2007 Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion following changes to European prescribing information
13/12/2007 Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment
09/12/2007 New data show Glivec® halts progression to advanced stages of life-threatening form of leukemia in sixth year of treatment
02/12/2007 Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration
30/11/2007 Novartis completes its fifth share repurchase program
28/11/2007 Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
21/11/2007 CIBA Vision, the eye care unit of Novartis, announces settlement of patent litigation with CooperVision, Inc.
19/11/2007 United Kingdom and Germany suspend marketing and sale of Prexige® pending outcome of European regulatory review
15/11/2007 New data for Menveo(TM) vaccine show excellent immune response and broad protection for infants against meningococcal meningitis
06/11/2007 New Galvus® clinical data reinforces efficacy profile; safety update provided to regulatory agencies
29/10/2007 Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
22/10/2007 Voltaren® Gel receives US regulatory approval as the first approved topical prescription treatment for pain associated with osteoarthritis
18/10/2007 Novartis delivers record earnings in first nine months of 2007 thanks to strong operational performance and divestment gains
05/10/2007 Aclasta® receives European approval as first once-yearly treatment for postmenopausal osteoporosis
28/09/2007 Novartis and Massachusetts Institute of Technology (MIT) in new partnership aimed at transforming pharmaceutical manufacturing
28/09/2007 Galvus® receives European approval as new treatment for type 2 diabetes with broad range of indications
27/09/2007 Prexige® receives ''not approvable'' letter in the US despite being one of the most studied COX-2 inhibitors
24/09/2007 Exelon® patch receives European Union approval, the first skin patch therapy to treat Alzheimer's disease
21/09/2007 Tasigna® recommended for European approval to treat rare form of leukemia no longer responding to Glivec®
21/09/2007 Eucreas®, a single-tablet combination of Galvus® and metformin, recommended for EU approval for type 2 diabetes
18/09/2007 First osteoporosis study in patients with hip fracture finds once-yearly Aclasta®-Reclast® prevents additional fractures and improves survival
17/09/2007 New data for Galvus® provide further evidence of robust efficacy and tolerability in treating patients with type 2 diabetes
14/09/2007 Novartis completes agreement with Bayer Schering related to Betaseron® rights and manufacturing
10/09/2007 US federal appeals court temporarily stops Teva from selling its generic version of the Novartis medicine Famvir®
07/09/2007 Novartis to defend its intellectual property rights for Famvir® despite an at-risk generic launch in US
05/09/2007 Cubicin® receives European approval to expand use to treating two additional types of life-threatening hospital infections
03/09/2007 Novartis completes divestment program with transfer of Gerber baby foods business
02/09/2007 Study shows Rasilez®, the first and only approved direct renin inhibitor, reduces a marker of heart failure severity and is well-tolerated
31/08/2007 Sandoz Receives European Commission Approval for biosimilar epoetin alfa
29/08/2007 Novartis announces the retirement of Urs Baerlocher
27/08/2007 Rasilez® receives EU approval, the first major innovation in high blood pressure treatment for more than a decade
18/08/2007 Reclast® receives US regulatory approval as first and only once-yearly treatment for women with postmenopausal osteoporosis
16/08/2007 Novartis starts US shipment of Fluvirin® allowing for early influenza vaccination of millions of Americans
10/08/2007 FDA grants additional six months marketing exclusivity for the high blood pressure medicine Diovan®
06/08/2007 Novartis concerned Indian court ruling will discourage investments in innovation needed to bring better medicines to patients
25/07/2007 Tasigna® approved in Switzerland based on impressive efficacy in patients with a form of leukemia no longer responding to Glivec®
23/07/2007 Novartis completes its fourth share repurchase program
20/07/2007 New data show Tekturna® and Diovan® used together provide additive blood pressure reductions
19/07/2007 Exelon® skin patch recommended for European approval, the first use of this new technology to treat patients with Alzheimer's disease
19/07/2007 Aclasta® recommended for European approval as the first once-yearly treatment for women with postmenopausal osteoporosis
19/07/2007 Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion recommending European Union approval
17/07/2007 Novartis delivers strong performance in first half of 2007 (H1 - Report)
09/07/2007 Exelon®Patch, the first and only skin patch for the treatment of Alzheimer's disease, receives first worldwide approval in US
03/07/2007 Novartis plans 30% increase in US supplies of Fluvirin® influenza vaccines and delivery of 40 million doses for 2007/2008 season
02/07/2007 Novartis completes divestment of Medical Nutrition business
02/07/2007 Novartis enhances its vaccine pipeline by gaining access to Intercell's key technologies and vaccines programs
25/06/2007 New data from multiple studies show Galvus® delivers consistent and robust blood sugar control in patients with type 2 diabetes
22/06/2007 Sandoz receives positive EU opinion for approval of epoetin alfa biosimilar
22/06/2007 Rasilez®, an important new treatment for high blood pressure, receives positive opinion recommending European Union approval
21/06/2007 Exforge® receives final US approval as new and powerful treatment option for patients with high blood pressure
15/06/2007 Prexige® study shows significantly less impact on blood pressure than ibuprofen in osteoarthritis patients with controlled hypertension
13/06/2007 Novartis gains European approval for its innovative flu vaccine Optaflu®
11/06/2007 US court allows Teva to resume US sales of its generic version of Lotrel
04/06/2007 Study shows one year of Glivec® reduces risk of cancer returning by 82% following surgery for gastrointestinal stromal tumors
29/05/2007 US court continues to prevent Teva from shipping any additional generic copies of the high blood pressure medicine Lotrel
21/05/2007 Exforge® helps vast majority of patients effectively control their blood pressure after failing on other medicines, according to new clinical data
21/05/2007 Single-tablet combination of Tekturna® and diuretic, an important new option for people with high blood pressure, submitted for US approval
08/05/2007 Focetria®, the Novartis pandemic influenza vaccine, receives European Union approval
30/04/2007 Sebivo® approved in European Union as a new first-line treatment for chronic hepatitis B
27/04/2007 Optaflu®, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval
27/04/2007 Diovan® achieved 40% reduction in stroke and cardiovascular events in landmark Jikei Heart Study
26/04/2007 Over 10 000 Novartis associates worldwide take part in Community Partnership Day
25/04/2007 Novartis delivers 4.7 million treatments of anti-malarial medicine to Tanzania on Africa Malaria Day
25/04/2007 Novartis expands portfolio of respiratory medicines by acquiring rights to a novel therapeutic vaccine against nicotine addiction
23/04/2007 Novartis with dynamic growth in the 2007 first quarter (Q1 - Media release)
23/04/2007 Novartis with dynamic growth in the 2007 first quarter (Q1 - Report)
19/04/2007 Novartis expands late-stage oncology pipeline with AS1404, a novel agent shown to break down blood vessels that support tumor growth
17/04/2007 Reclast® receives US approval as a highly effective treatment for patients with Paget's disease of the bone
12/04/2007 Positive results prompt US National Cancer Institute to make Glivec® available to patients in post-surgical GIST study
12/04/2007 Novartis completes its business portfolio restructuring, divesting Gerber for USD 5.5 billion to Nestlé
30/03/2007 Novartis suspends US marketing and sales of Zelnorm(R) in response to request from FDA
26/03/2007 Tekturna®, first new type of high blood pressure medicine in a decade, provides additional blood pressure reduction when used with Diovan®
26/03/2007 Novartis to launch its own branded version of a leading multiple sclerosis therapy through agreement with Bayer Schering Pharma
13/03/2007 Novartis ranked No. 1 among pharmaceutical companies in Fortune magazine's ''World's Most Admired Companies'' survey
06/03/2007 Novartis shareholders approve all resolutions at 2007 Annual General Meeting, including dividend increase and Board elections
06/03/2007 Tekturna® - the first new type of high blood pressure medicine in more than a decade - receives its first approval in the US
03/03/2007 Novartis to market newly approved Procleix® Tigris® System in U.S. as the first fully automated system for West Nile virus blood screening
02/03/2007 Sebivo® approved in China for treatment of chronic hepatitis B, the nation's second leading cause of death
26/02/2007 Leading proxy advisory firm ISS recommends Novartis shareholders to approve all Board proposals at next Annual General Meeting
26/02/2007 Novartis committed to making Galvus® available for patients with type 2 diabetes after US regulators issue ''approvable letter''
23/02/2007 Focetria® pandemic influenza vaccine receives positive European Union regulatory agency opinion supporting approval
15/02/2007 Novartis seeking clarity in Indian patent laws, a critical incentive for long-term R&D investments into better medicines for patients
12/02/2007 Novartis, The Broad Institute, and Lund University announce release of genome-wide analysis of genes associated with type 2 diabetes and related metabolic disorders
09/02/2007 Novartis proposes approval of tenth consecutive higher dividend payment and election of new Board member at Annual General Meeting
01/02/2007 Novartis files 2006 annual report on Form 20-Fwith the US Securities and Exchange Commission
25/01/2007 Novartis Institute for Tropical Diseases inaugurates new Indonesian research initiative to study dengue fever, tuberculosis and malaria
24/01/2007 Lucentis® receives approval in the European Union - the first drug to improve vision in patients with wet AMD, a leading cause of blindness
18/01/2007 Exforge® approved in Europe as powerful new blood pressure therapy combining two leading medications in a single pill
18/01/2007 Novartis strategic healthcare portfolio drives sustained strong performance with record full-year results in 2006
17/01/2007 Novartis receives US government contract to further develop a novel antigen technology that could extend vaccine supplies in a pandemic outbreak
22/12/2006 Exforge® receives US regulatory approval as a new and highly effective treatment option for patients with high blood pressure
14/12/2006 Novartis making significant progress in creating new strategic growth platform in human vaccines, names site for new division headquarters
14/12/2006 Novartis to further focus on healthcare, reaching agreement to sell its Medical Nutrition business
14/12/2006 Novartis announces three-month extension of US regulatory review period for Tekturna®
11/12/2006 Pivotal submission data shows Tasigna® achieved impressive response rates in chronic myeloid leukemia patients no longer helped by Glivec®
06/12/2006 Glivec® demonstrates highest five-year overall survival rate in history of treatment for patients with chronic myeloid leukemia
06/12/2006 New evidence reinforces efficacy and tolerability of Galvus® as a new once-daily oral treatment option for patients with type 2 diabetes
Media release archive:    
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.